(Q36982574)

17 August 2017

1 reference

title

The treatment of dyslipidemia--what's left in the pipeline? (English)

1 reference

17 August 2017

1 reference

4

Dieter Steinhilber

1 reference

Manfred Schubert-Zsilavecz

17 August 2017

series ordinal

5

object named as

Manfred Schubert-Zsilavecz

1 reference

17 August 2017

Oliver Rau

1

1 reference

17 August 2017

Heiko Zettl

series ordinal

2

1 reference

17 August 2017

Laura Popescu

series ordinal

3

1 reference

17 August 2017

1 February 2008

1 reference

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

2

1 reference

17 August 2017

206-221

1 reference

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

17 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

HDL elevators and mimetics--emerging therapies for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The UKPDS: implications for the dyslipidaemic patient

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Hypertriglyceridemia and the fibrate trials

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Fibrates, dyslipoproteinaemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPARs: therapeutic targets for metabolic disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPARs and the complex journey to obesity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Principles for modulation of the nuclear receptor superfamily

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The RXR heterodimers and orphan receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPAR Tissue Distribution and Interactions with Other Hormone-Signaling Pathways

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Therapeutic roles of peroxisome proliferator-activated receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in seru

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPAR delta: a dagger in the heart of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The mode of action of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The many faces of PPARgamma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Subchronic urinary bladder effects of muraglitazar in male rats

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Peroxisome-proliferator-activated receptors and cancers: complex stories

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The PPARs: from orphan receptors to drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPAR dual agonists: are they opening Pandora's Box?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Design and synthesis of a novel class of dual PPARgamma/delta agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Transcriptional regulation of metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Identification of a nuclear receptor that is activated by farnesol metabolites

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

FXR, a therapeutic target for bile acid and lipid disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

A natural product that lowers cholesterol as an antagonist ligand for FXR.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Role of CETP inhibitors in the treatment of dyslipidemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Lipid transfer proteins (LTP) and atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

The failure of torcetrapib: was it the molecule or the mechanism?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Lipid-altering agents: the future

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Molecular mechanisms of cholesterol absorption and transport in the intestine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

S-8921, an ileal Na+/bile acid cotransporter inhibitor decreases serum cholesterol in hamsters

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Clinical results with AGI-1067: a novel antioxidant vascular protectant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Apolipoprotein A-I(Milano): current perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Synthetic peptide analogs of apolipoproteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effect of ACAT inhibition on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Influence of oxygen inhalation on cholesterol metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

5-Carboxamido-1,3,2-dioxaphosphorinanes, potent inhibitors of MTP.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700165

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700165

1 reference

17 August 2017

1 reference